• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Boston Scientific CEO talks pricing pressure for drug-eluting stents

October 25, 2018 By Sarah Faulkner

Boston ScientificOn an earnings call with analysts this week, Boston Scientific (NYSE:BSX) CEO Mike Mahoney touted the momentum of his company’s drug-eluting stent portfolio but noted that the technologies continue to face headwinds in the U.S. thanks to pricing pressure.

The Mass.-based company reported third-quarter profits of $432 million, or 31¢ per share, on sales of $2.39 billion for the three months ended Sept. 30, for a bottom-line gain of 52.7% on sales growth of 7.7% compared with Q3 2017.

Adjusted to exclude one-time items, earnings per share were 35¢, a penny ahead of Wall Street, where analysts were looking for sales of $2.40 billion.

On the call, Mahoney noted that the company launched its Eluvia drug-eluting stent in the U.S. during the third quarter, following positive data from the first head-to-head trial of its kind and an early FDA approval.

“We believe Eluvia has significant market opportunity given the large addressable patient population, its differentiated, sustained-release technology, and its demonstrated superior clinical outcomes with reduced need for reintervention. This launch is in the very early stages, but our sales team is fully trained. We’ve already received significant interest from physicians and healthcare systems around the country,” Mahoney said.

Boston Scientific also enrolled the first patient in a trial assessing a drug-eluting stent for below-the-knee lesions and completed enrollment in a trial evaluating its Ranger drug-coated balloon. The company is hoping to launch its Ranger device in the U.S. in 2020.

In coronary drug-eluting stents, “we continue to work through competitive pricing headwinds, particularly in the U.S.,” Mahoney said.

The chief executive touted the recent FDA approval of Boston Scientific’s new drug-eluting stent, Promus Elite, and explained that he hoped the device would provide “important support to our global tier DES segmentation strategy.”

Mahoney described drug-eluting stents as the company’s “toughest segment,” thanks to pricing pressure.

“But this Elite solution will be a nice segmented offering because what it will enable us to do is offer customers who want better economics, a permanent polymer stent to match our two biggest competitors, global competitors, and then to further differentiate our Synergy bioresorbable polymer at more of a premium. So, it’s a nice way for us to position best in class delivery system with Synergy with a durable polymer to match some of the competitive headwinds that we see in price. And then use that to then further differentiate Synergy a bit more. So, I think it’s a nice strategy, and hopefully we’ll see some improvement next year in DES,” he added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Boston Scientific

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS